Related Experiment Video

Updated: May 6, 2026

An Experimental Model of Myocardial Infarction for Studying Cardiac Repair and Remodeling in Knockout Mice
09:29

An Experimental Model of Myocardial Infarction for Studying Cardiac Repair and Remodeling in Knockout Mice

Published on: July 14, 2023

1.4K

The emerging role of Galectin-3 and ST2 in heart failure: practical considerations and pitfalls using novel

George Karayannis1, Filippos Triposkiadis, John Skoularigis

  • 1Department of Cardiology, University Hospital of Larissa, School of Medicine, University of Thessaly, P.O. Box 1425, 411 10, Larissa, Greece.

Current Heart Failure Reports
|October 22, 2013
PubMed

Insights

Novel biomarkers Galectin-3 (GAL3) and sST2 show promise for heart failure (HF) management, potentially overcoming limitations of natriuretic peptides. These biomarkers aid in diagnosis, prognosis, and treatment guidance for HF patients.

Area of Science:

  • Cardiology
  • Biomarker Discovery
  • Molecular Biology

Background:

  • Heart failure (HF) remains a major cause of death and hospitalization globally.
  • Current therapies have not sufficiently reduced HF hospitalization rates.
  • Natriuretic peptides are useful but have limitations due to biological variations.

Purpose of the Study:

  • To review existing data on Galectin-3 (GAL3) and sST2 as novel biomarkers in heart failure.
  • To explore the potential advantages of GAL3 and sST2 over traditional biomarkers.
  • To assess the utility of GAL3 and sST2 in clinical practice for HF management.

Main Methods:

  • Literature review of current research on GAL3 and sST2 in HF.
  • Analysis of data regarding the diagnostic and prognostic properties of these biomarkers.
  • Comparison of GAL3 and sST2 with natriuretic peptides in HF contexts.

Main Results:

  • GAL3 and sST2 are emerging biomarkers with potential in HF.
  • These biomarkers may offer advantages over natriuretic peptides due to fewer biological variations.
  • They can be used independently or combined with natriuretic peptides.

Conclusions:

  • GAL3 and sST2 represent promising advancements in HF biomarker research.
  • Their application could enhance the identification and management of heart failure.
  • Further clinical validation is essential to fully integrate these biomarkers into practice.

More Related Videos

Viral Transgene Expression in Rodent Hearts and the Assessment of Cardiac Arrhythmia Risk05:15

Viral Transgene Expression in Rodent Hearts and the Assessment of Cardiac Arrhythmia Risk

Published on: July 27, 2022

1.8K

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
2.3K
Heart Failure III: Clinical Manifestations01:26

Heart Failure III: Clinical Manifestations

Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...
1.5K
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
812
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
635
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
769
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
2.0K